All Videos

Linda Stein Gold, MD, reviews phase III data for the topical agent tapinarof for the treatment of plaque psoriasis.

Linda Stein Gold, MD, and Jennifer Soung, MD, provides an overview of the safety profile and topical vehicle of roflumilast for the treatment of plaque psoriasis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, evaluate the effect of the rapidly changing therapeutic landscape in atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the burden of atopic dermatitis and discuss how they talk to patients about the impact their disease has on their lives.

Linda Stein Gold, MD, discusses the itch response of roflumilast for the treatment for plaque psoriasis.

Experts in plaque psoriasis discuss the primary endpoint data responses of roflumilast in the DERMIS-1/DERMIS-2 trials.

Dr Leon Kircik, comments on the impact the multiple formulations of isotretinoin had on acne care; and highlights the efficacy differences between generic vs brand formulations.

Leon Kircik, M.D., discusses the indication of isotretinoin for use in patients suffering from acne, highlighting the difference between high and low dose administration needs.

An expert in acne management shares her insight into the patient characteristics a provider needs to consider when assessing the risk/benefit of a therapeutic agent for the management of acne.

Dr Zoe Diana Draelos discusses the role of ancillary skin care products in the management of acne and stresses the importance of setting patient expectations.

Zoe Diana Draelos, MD comments on the importance of tailoring acne treatments based on disease severity and the ability to target key acne pathogenesis factors.

Jennifer Soung, MD, provides an overview of the phase III trials, DERMIS-1/DERMIS-2, in which roflumilast was used to treat plaque psoriasis

Linda Stein Gold, MD, and Jennifer Soung, MD, provide an overview of the different, evidence-based topical strategies for treating plaque psoriasis.

Nada Elbuluk, MD, and David Rosmarin, MD, provide advice to physicians on the management of vitiligo.

Nada Elbuluk, MD, and David Rosmarin, MD, share their thoughts on future treatments in the pipeline for vitiligo.

Drs Raj Chovatiya and Neal Bhatia summarize their final thoughts on the available treatment options for the management of atopic dermatitis.

Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.

Experts in dermatology discuss the use of oral and topical JAK inhibitors in clinical practice and their reflection of overarching treatment guidelines and indications.

Drs Raj Chovatiya and Neal Bhatia highlight the biological targets of current and emerging treatments for the management of atopic dermatitis and discuss the importance of safety and long-term data.

Raj Chovatiya, MD, PhD, and Neal Bhatia, MD, share their thoughts on the clinical implications of the rapid expansion of the atopic dermatitis treatment armamentarium.

Hilary Baldwin, M.D., shares her hopes for the future of acne treatment and provides her practice pearls from a panel discussion surrounding the management of patients suffering from acne.

An expert in acne management shares her insight on the current needs and the role of consensus guidelines in the management of patients suffering from acne.

Dr Hilary Baldwin discusses her treatment considerations and approach in the management of patients with mild to moderate acne, highlighting the benefit of combination therapy.

Hilary Baldwin, M.D., comments on the impact of the recent approval of clascoterone cream 1% in the topical acne armamentarium of patients suffering from acne.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, share take-home messages on the impact of the generalized pustular psoriasis study.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, discuss study limitations regarding health records in generalized pustular psoriasis and how the number of flares could be underestimated.

Raj Chovatiya, MD, PhD, gives a preview of his discussions on topical formulations of atopic dermatitis and advancing therapeutic expectations at this weekend’s RAD conference.

Mona Shahriari, MD, Assistant Clinical Professor of Dermatology at Yale University School of Medicine, shares what she is looking forward to at the Revolutionizing Atopic Dermatitis virtual conference.

Korey Capozza, MPH, Executive Director of Global Parents for Eczema Research, shares what she is looking forward to at the Revolutionizing Atopic Dermatitis virtual conference.

Jonathan Silverberg, MD, PHD, MPHS, talks about the exciting highlights of the Revolutionizing Atopic Dermatitis virtual conference on December 11.